The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study

References

• GersteinHCPogueJMannJFEThe relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysisDiabetologia20054891749175516059716
   PubMed Web of Science ®Google Scholar
• SelvinEMarinopoulosSBerkenblitGMeta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitusAnn Intern Med2004141642143115381515
   PubMed Web of Science ®Google Scholar
• LaaksoMDiabetes as a ‘cardiovascular disease equivalent’: implications for treatmentNat Clin Pract Cardiovasc Med200851168268318797431
   PubMedGoogle Scholar
• Action to Control Cardiovascular Risk in Diabetes Study GroupGersteinHCMillerMEEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• JørgensenCHGislasonGHAnderssonCEffects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention – a retrospective nationwide cohort studyCardiovasc Diabetol201095420843380
   PubMed Web of Science ®Google Scholar
• SimpsonSHMajumdarSRTsuyukiRTEurichDTJohnsonJADose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort studyCMAJ2006174216917416415461
   PubMed Web of Science ®Google Scholar
• DeleaTEEdelsbergJSHagiwaraMOsterGPhillipsLSUse of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort studyDiabetes Care200326112983298914578227
   PubMed Web of Science ®Google Scholar
• MasoudiFAInzucchiSEWangYHavranekEPFoodyJMKrumholzHMThiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational studyCirculation2005111558359015699279
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med2007356242457247117517853
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-Year follow-up of intensive glucose control in type 2 diabetesN Engl J Med2008359151577158918784090
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2015Diabetes Care201538SupplS1S93
   PubMed Web of Science ®Google Scholar
• Guidance for industry: diabetes mellitus – evaluation cardiovascular risk in new antidiabetic therapies to treat type 2 diabetesUS Food and Drug Administration2008 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid-ances/ucm071627.pdfAccessed January 15, 2016
   Google Scholar
• WhiteWBCannonCPHellerSRAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med2013369141327133523992602
   PubMed Web of Science ®Google Scholar
• SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317132623992601
   PubMed Web of Science ®Google Scholar
• GreenJBBethelMAArmstrongPWEffect of sitagliptin on cardiovascular outcomes in type 2 diabetesN Engl J Med2015373323224226052984
   PubMed Web of Science ®Google Scholar
• UdellJACavenderMABhattDLChatterjeeSFarkouhMESciricaBMGlucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trialsLancet Diabetes Endocrinol20153535636625791290
   PubMed Web of Science ®Google Scholar
• FrederichRAlexanderJHFiedorekFTA systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetesPostgrad Med20101223162720463410
   PubMed Web of Science ®Google Scholar
• MonamiMAhrénBDicembriniIMannucciEDipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trialsDiabetes Obes Metab201315211212022925682
   PubMed Web of Science ®Google Scholar
• ScheenAJCardiovascular effects of gliptinsNat Rev Cardiol2013102738423296071
   PubMed Web of Science ®Google Scholar
• KimSCGlynnRJLiuJEverettBMGoldfineABDipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort studyActa Diabetol20145161015102325311055
   PubMed Web of Science ®Google Scholar
• HamppCBorders-HemphillVMoenyDGWysowskiDKUse of antidiabetic drugs in the US, 2003–2012Diabetes Care20143751367137424623020
   PubMed Web of Science ®Google Scholar
• KimYGHahnSOhTJKwakSHParkKSChoYMDifferences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysisDiabetologia201356469670823344728
   PubMed Web of Science ®Google Scholar
• HermanWHEdelsteinSLRatnerREEffectiveness and cost-effectiveness of diabetes prevention among adherent participantsAm J Manag Care201319319420223544761
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research GroupLong-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes StudyDiabetes Care201235473173722442396
   PubMed Web of Science ®Google Scholar
• JohnsonJASimpsonSHTothELMajumdarSRReduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetesDiabet Med200522449750215787679
   PubMed Web of Science ®Google Scholar
• FontbonneACharlesMAJuhan-VagueIThe effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study GroupDiabetes Care19961999209268875083
   PubMed Web of Science ®Google Scholar
• KitabchiAETemprosaMKnowlerWCRole of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metforminDiabetes20055482404241416046308
   PubMed Web of Science ®Google Scholar
• HiattWRKaulSSmithRJThe cardiovascular safety of diabetes drugs – insights from the rosiglitazone experienceN Engl J Med2013369141285128723992603
   PubMed Web of Science ®Google Scholar
• RawsonNSReview of the quality of observational studies of the association between rosiglitazone and acute myocardial infarctionJ Popul Ther Clin Pharmacol2014212e214e23224893215
   PubMedGoogle Scholar
• FDA Drug Safety Communication: updated risk evaluation and mitigation strategy (REMS) to restrict access to rosiglitazone-containing medicines including Avandia, Avandamet, and AvandarylUS Food and Drug Administration2011 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm255005.htmAccessed January 15, 2016
   Google Scholar
• FriedrichJOBeyeneJAdhikariNKRosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approachesBMC Res Notes20092519134216
   PubMedGoogle Scholar
• DiamondGABaxLKaulSUncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular deathAnn Intern Med2007147857858117679700
   PubMed Web of Science ®Google Scholar
• FDA requires removal of certain restrictions on the diabetes drug AvandiaUS Food and Drug Administration2013 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htmAccessed January 15, 2016
   Google Scholar
• HomePDPocockSJBeck-NielsenHRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialLancet200937396812125213519501900
   PubMed Web of Science ®Google Scholar
• KungJHenryRRThiazolidinedione safetyExpert Opin Drug Saf201211456557922616948
   PubMed Web of Science ®Google Scholar
• ThornberryNAGallwitzBMechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)Best Pract Res Clin Endocrinol Metab200923447948619748065
   PubMed Web of Science ®Google Scholar
• MaRCChanJCType 2 diabetes in East Asians: similarities and differences with populations in Europe and the United StatesAnn N Y Acad Sci20131281649123551121
   PubMed Web of Science ®Google Scholar
• AsoYOzekiNTerasawaTSerum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylureaTransl Res20121591253122153807
   PubMed Web of Science ®Google Scholar
• NakagamiTDECODA Study GroupHyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian originDiabetologia200447338539414985967
   PubMed Web of Science ®Google Scholar
• DeaconCFDipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative reviewDiabetes Obes Metab201113171821114598
   PubMed Web of Science ®Google Scholar
• AhrénBEmerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetesExpert Opin Emerg Drugs200813459360719046129
   PubMed Web of Science ®Google Scholar
• PhungOJScholleJMTalwarMColemanCIEffect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetesJAMA2010303141410141820388897
   PubMed Web of Science ®Google Scholar
• PratleyRESalsaliAInhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetesCurr Med Res Opin200723491993117407649
   PubMed Web of Science ®Google Scholar
• Williams-HermanDRoundESwernASSafety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysisBMC Endocr Disord200881418954434
   PubMedGoogle Scholar
• GallwitzBSitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetesDrugs Today (Barc)2007431132517315049
   PubMed Web of Science ®Google Scholar